Lifecore Biomedical, Inc. LFCR
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 09/30/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -18.60% | -6.25% | -34.02% | 25.92% | 25.92% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -18.60% | -6.25% | -34.02% | 25.92% | 25.92% |
| Cost of Revenue | -20.68% | -1.65% | -25.99% | 20.71% | 20.71% |
| Gross Profit | -12.39% | -13.64% | -54.68% | 44.63% | 44.63% |
| SG&A Expenses | -29.18% | -11.24% | -37.41% | -27.59% | -27.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.29% | -5.80% | -29.86% | 1.15% | 1.15% |
| Operating Income | 70.85% | -11.45% | -33.97% | 66.24% | 66.24% |
| Income Before Tax | -314.51% | -450.54% | -1.08% | 40.58% | 40.58% |
| Income Tax Expenses | -84.68% | -30.30% | 637.50% | 1,432.00% | 1,432.00% |
| Earnings from Continuing Operations | -301.20% | -436.70% | -1.43% | 38.44% | 38.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -301.20% | -436.70% | -1.43% | 38.44% | 38.44% |
| EBIT | 70.85% | -11.45% | -33.97% | 66.24% | 66.24% |
| EBITDA | 239.59% | 5.59% | -251.15% | 84.68% | 84.68% |
| EPS Basic | -271.49% | -243.04% | 9.42% | 44.52% | 44.52% |
| Normalized Basic EPS | -309.60% | -70.57% | -63.77% | 42.07% | 42.07% |
| EPS Diluted | -271.49% | -243.04% | 9.53% | 44.94% | 44.94% |
| Normalized Diluted EPS | -309.60% | -70.57% | -63.77% | 42.07% | 42.07% |
| Average Basic Shares Outstanding | 1.18% | 1.53% | 1.23% | 21.22% | 21.22% |
| Average Diluted Shares Outstanding | 1.18% | 1.53% | 1.23% | 21.22% | 21.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |